Researchers at UVA developed an AI imaging tool using PET/MR to distinguish treatment effects from tumor progression in glioblastoma patients.
Key Details
- 1AI tool analyzes PET/MR imaging findings in glioblastoma cases.
- 2Distinguishes between tissue changes due to treatment vs. tumor progression.
- 3Current monitoring approaches often require a waiting period of 3+ months.
- 4Faster distinction could enable earlier treatment modification for recurrence.
- 5Method developed by a University of Virginia team.
Why It Matters
Improved differentiation between treatment effects and recurrence could allow clinicians to adjust therapies more quickly, potentially improving outcomes for a highly aggressive brain cancer. This underlines the growing significance of AI-assisted multi-modal imaging in oncology workflows.
Source
Health Imaging
Related News
•AuntMinnie
AI-Based Slab Reconstruction Streamlines Digital Breast Tomosynthesis
AI-driven slab reconstruction in DBT improves workflow efficiency without compromising diagnostic accuracy in breast cancer screening.
•AuntMinnie
AI Model Predicts Dosimetry for Lu-177 PSMA Therapy Using PET/CT
A machine learning PET/CT model shows promise for predicting radiation dose prior to Lu-177 PSMA therapy in prostate cancer patients.
•AuntMinnie
AI Model Uses Ultrasound to Assess Fetal Lung Maturity
Researchers demonstrated an AI model's strong accuracy in measuring fetal lung maturity from ultrasound images.